Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risk of pancreatic adenocarcinoma in chronic pancreatitis.

D Malka1, P Hammel, F Maire

  • 1Fédération Médico-Chirurgicale d'Hépato-Gastro-Entérologie, Hôpital Beaujon, Université Paris VII, Assistance Publique-Hôpitaux de Paris, Clichy, France.

Gut
|November 13, 2002
PubMed
Summary

Patients with chronic pancreatitis (CP) face a significantly higher risk of developing pancreatic cancer. This study quantifies this increased risk, highlighting the importance of monitoring patients with CP for pancreatic cancer surveillance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intra-arterial hepatic chemotherapy in metastatic colorectal cancer: differences between oxaliplatin-naive versus oxaliplatin-pretreated patients.

ESMO gastrointestinal oncology·2026
Same author

Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis.

ESMO gastrointestinal oncology·2026
Same author

Codon-specific <i>KRAS</i> mutations predict survival in advanced pancreatic cancer.

ESMO gastrointestinal oncology·2026
Same author

Reply to letter comments on: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).

ESMO open·2025
Same author

Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative.

ESMO open·2025
Same author

Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).

ESMO open·2025

Area of Science:

  • Gastroenterology and Hepatology
  • Oncology
  • Epidemiology

Background:

  • Assessing pancreatic cancer risk in chronic pancreatitis (CP) patients is challenging.
  • Prior studies reported variable relative risks (2.3-18.5) for pancreatic cancer in CP patients.
  • Existing research often relied on case-control designs or registry data.

Purpose of the Study:

  • To prospectively evaluate the incidence of pancreatic cancer in a cohort of patients with proven chronic pancreatitis.
  • To accurately quantify the standardized incidence ratio (SIR) of pancreatic cancer in this high-risk group.

Main Methods:

  • A prospective, single-center cohort study of 373 patients with proven chronic pancreatitis (CP).
  • Median follow-up of 9.2 years (range 2.0-34.8 years) to exclude pancreatitis revealing cancer.

Related Experiment Videos

  • Calculation of age and sex-standardized incidence ratio (SIR) using French National Cancer Register data.

    • Main Results:

    • Four cases of pancreatic adenocarcinoma (1.1%) were observed over 3437 patient-years.
    • The standardized incidence ratio (SIR) was 26.7 (95% CI 7.3-68.3; p=0.00002).
    • An adjusted analysis yielded an SIR of 19.0 (95% CI 5.2-48.8; p=0.00007).

    Conclusions:

    • Patients with chronic pancreatitis exhibit a markedly increased risk of pancreatic cancer.
    • The findings underscore the need for vigilant pancreatic cancer surveillance in individuals with CP.
    • This study provides robust evidence of elevated pancreatic cancer risk in CP.